Research programme: anti-CD155 antibodies - Biotecnol
Latest Information Update: 14 Jun 2012
At a glance
- Originator Biotecnol SA
- Class Antibodies
- Mechanism of Action CD antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 15 Nov 2007 Preclinical trials in Solid tumours in Portugal (Parenteral)
- 15 Nov 2007 The anti-CD155 antibody programme is available for licensing worldwide (http://www.biotecnol.com/default.aspx?classification=00003201:00000001)